The transaction involves future milestone payments of EUR 4m.
The acquisition is believed to expand Repligen’s product offering, customer base and manufacturing capacity.
The combined company will also drive the growth of the monoclonal antibody market.
Novozymes Biopharma manufactures and supplies growth factors used in mammalian cell culture and Protein A affinity ligands used in the production of monoclonal antibodies, under cGMP.